

**DIAGNOSTIC & THERAPEUTIC CENTER OF ATHENS 'HYGEIA S.A.'**

S.A Registration No. 13165/06/B/86/14

**4, KIFISSIAS AVENUE & ERYTHROU STAVROU STR, GR-15123 MAROUSI, ATHENS**  
Data and information for the period from January 1st 2009 to September 30th 2009

(pursuant to resolution no. 4/507/28.04.2009 by the Capital Market Commission Board of Directors)

The data and information below resulting from the financial statements aim at an overall presentation of the Group and parent company Diagnostic and Therapeutic Center of Athens-Hygeia S.A financial situation and results. We, therefore, propose to readers, prior to any investment choice or transaction with the issuer, to visit the issuer's web address where the financial statements and the audit report by the chartered accountant, when required, are posted.

COMPANY GENERAL INFORMATION					INCOME STATEMENT				
Web address: www.hygeia.gr					Amounts in €				
Approval date by the Board of Directors of the interim condensed financial information					Group				
dated September 30, 2009: 18/11/2009					01/01-30/09/2009 01/01-30/09/2008 01/07-30/09/2009 01/07-30/09/2008				
FINANCIAL POSITION STATEMENT INFORMATION									
Amounts in €									
Group		Company							
	30/09/2009	31/12/2008	30/09/2009	31/12/2008					
<b>ASSETS</b>									
Property, plant and equipment	250,036,682	233,278,633	102,934,348.	101,672,447					
Property investment	168,030	169,314	168,029.5	169,314					
Intangible Assets	138,356,076	139,817,825	3,385,182.61	3,679,886					
Other non current assets	242,054,408	241,536,502	366,223,009.	371,049,131					
Inventories	11,345,715	9,854,756	2,321,581.57	2,183,995					
Accounts Receivables	109,300,720	89,362,194	58,373,798.	42,933,193					
Other current assets	31,074,141	199,576,107	22,501,892.93	189,807,965					
<b>TOTAL ASSETS</b>	<b>782,335,772</b>	<b>913,595,331</b>	<b>555,907,843.</b>	<b>711,495,931</b>					
<b>EQUITY AND LIABILITIES</b>									
Share capital	51,508,673	51,508,673	51,508,673.1	51,508,673					
Other equity items	268,297,265	288,632,091	264,920,447.	272,807,810					
<b>Total equity of parent company owners (a)</b>	<b>319,805,938</b>	<b>340,140,764</b>	<b>316,429,120</b>	<b>324,316,483</b>					
Minority interest(b)	31,400,667	38,954,767	0	0					
<b>Total equity (c) = (a) + (b)</b>	<b>351,206,605</b>	<b>379,095,531</b>	<b>316,429,120</b>	<b>324,316,483</b>					
Long term loans	33,885,562	33,135,331	0	0					
Provisions/Other long term liabilities	75,689,002	73,153,275	19,801,775	19,320,025					
Short term loans	231,900,281	328,778,624	189,000,000	312,953,140					
Other short term liabilities	89,654,322	99,432,570	30,676,947	54,906,283					
<b>Total liabilities (d)</b>	<b>431,129,167</b>	<b>534,499,800</b>	<b>239,478,722</b>	<b>387,179,448</b>					
<b>TOTAL EQUITY &amp; LIABILITIES (c) + (d)</b>	<b>782,335,772</b>	<b>913,595,331</b>	<b>555,907,843</b>	<b>711,495,931</b>					
<b>CASH FLOW STATEMENT</b>									
Amounts in €									
Group		Company							
	01/01-30/09/2009	01/01-30/09/2008	01/01-30/09/2009	01/01-30/09/2008					
<b>Operating activities</b>									
Profit before tax	16,032.145	16,927.366	15,755.491	13,601.253					
Plus / minus adjustments for:									
Depreciations	14,883.010	11,140.898	5,724.614	5,217.465					
Provisions	4,075.314	3,215.941	1,344.287	1,364.705					
Income from use of provisions of previous financial years	(81.211)	0	0	0					
Results (income, expenses, profits and losses) from investment activities	(2,924.915)	(7,544.155)	(11,120.533)	(18,985.751)					
Subsidies depreciations	(90.148)	(78.044)	(19.661)	0					
Profit/(loss) from associates	(75.879)	(99.241)	0	0					
Interests on debt and similar charges	11,026.603	22,356.775	7,438.192	19,939.053					
Other	429.220	281.680	429.220	281.680					
Plus/minus adjustments for changes in working capital accounts or changes related to operating activities:									
Decrease/ (increase) in inventories	(1,488.751)	(1,340.753)	(137.587)	(269.960)					
Decrease / (increase) in receivables	(2,311.439)	(24,193.100)	(8,457.399)	(14,130.580)					
(Decrease) / increase in liabilities (minus banks)	(14,012.200)	3,936.316	3,063.559	(4,417.697)					
Minus:									
Interests on debt and similar paid up charges	(12,111.345)	(11,893.238)	(10,320.451)	(9,940.611)					
Tax paid	(5,454.104)	(3,571.338)	(354.365)	(1,202.843)					
<b>Total inflow / (outflow) from operating activities (a)</b>	<b>7,896.300</b>	<b>9,139.107</b>	<b>3,345.366</b>	<b>(8,543.286)</b>					
<b>Investment activities</b>									
Acquisition of subsidiaries, associates, joint ventures and other investments	(23,647.471)	(15,586.122)	(20,865.735)	(26,397.665)					
Purchase of tangible and intangible fixed assets	(31,167.448)	(19,836.369)	(6,761.505)	(7,280.132)					
Proceeds from tangible and intangible fixed assets sales	61.502	200.588	61.000	200.588					
Loans to associates	0	0	(6,996.807)	(250.000)					
Purchase of available for sale portfolio	(38.970)	(58.691)	0	0					
Interests received	1,874.791	6,462.654	1,762.697	6,412.607					
Dividends received	0	0	10,801.235	11,397.764					
<b>Total inflow / (outflow) from investment activities (b)</b>	<b>(52,917.596)</b>	<b>(28,817.940)</b>	<b>(21,999.115)</b>	<b>(15,916.838)</b>					
<b>Financing activities</b>									
Share capital increase receivables	0	250.000	0	0					
Proceeds from loans	308,183.897	333,183.717	273,000.000	316,877.814					
Repayment of loans	(408,115.039)	(57,914.206)	(400,015.300)	(42,213.661)					
settlement of liabilities from financing leases (amortizations)	(677.179)	(1,029.844)	0	(69.566)					
Capital return	(15,112.283)	(10,585.613)	(15,075.709)	(10,050.473)					
Dividends paid	(6,651.547)	(10,050.473)	(6,281.546)	(10,050.473)					
<b>Total inflow / (outflow) from financing activities (c)</b>	<b>(122,372.150)</b>	<b>253,853.581</b>	<b>(148,372.555)</b>	<b>254,493.641</b>					
<b>Net increase / (decrease) in cash and cash equivalents of the period (a) + (b) + (c)</b>	<b>(167,393.447)</b>	<b>234,174.748</b>	<b>(167,026.303)</b>	<b>230,033.517</b>					
<b>Cash and cash equivalents at the beginning of period</b>	<b>199,576.107</b>	<b>8,870.649</b>	<b>189,807.965</b>	<b>3,924.669</b>					
<b>Fx translation differences in cash and cash equivalents</b>	<b>(1,108.519)</b>	<b>11,321</b>	<b>(279.769)</b>	<b>0</b>					
<b>Cash and cash equivalents at the end of the period</b>	<b>31,074.141</b>	<b>243,056.718</b>	<b>22,501.893</b>	<b>233,958.186</b>					
<b>STATEMENT OF CHANGES IN EQUITY</b>									
Amounts in €									
Group		Company							
	30/09/2009	30/09/2008	30/09/2009	30/09/2008					
<b>Total equity at the beginning of the period (01.01.2009 καὶ 01.01.2008, respectively)</b>									
	379,095,531	358,480,635	324,316,483	329,791,544					
<b>Total comprehensive income after tax</b>									
	7,725,903	11,096,107	14,202,212	12,347,274					
<b>Direct changes in equity</b>									
	0	0	0	0					
Employees' stock option plan	429,220	281,680	429,220	281,680					
Differences from purchase of shareholdings in subsidiaries	(8,432.443)	0	0	0					
Minority interest	(3,079.384)	7,265.304	0	0					
Convertible bond loan reserve	(1,161.539)	2,630.070	(1,161.539)	2,630.070					
Distribution of dividends	(6,320.546)	(10,653.125)	(6,281.546)	(10,050.473)					
Capital return	(15,075.709)	(10,050.472)	(15,075.709)	(10,050.473)					
Impact from the subsidiary purchase consideration finalization	(1,974.430)	0	0	0					
<b>Total equity at the end of the period (30.09.2009 καὶ 30.09.2008, respectively)</b>	<b>351,206.603</b>	<b>359,050,199</b>	<b>316,429,121</b>	<b>324,949,622</b>					
<b>ADDITIONAL DATA AND INFORMATION</b>									
<p>1. The companies of HYGEIA Group with their respective shareholdings and their consolidation method in the consolidated financial statements for the period 1.1.2009 – 30.09.2009 are outlined in detail under notes 5 &amp; 10 of the Interim Financial Statements Notes.</p> <p>The latter also include the following companies:</p> <p>a) the 100% subsidiary "Obstetrics &amp; Gynaecology Clinic Evangelismos Ltd" holding directly the companies "Evangelismos Management Ltd", "AKESO KTIMATIKI" and "Evangelismos KTIMATIKI Ltd" with a 60% stake after acquiring control on 7.7.2008, b) the company "STEM HEALTH UNIREA S.A.", where HYGEIA SA holds an indirect participation of 25% through its 50% subsidiary "STEM HEALTH S.A.", after acquiring control on 18.9.2008 c) the "Genesis Holding A.S." Group where HYGEIA SA holds a direct participation of 50% after acquiring control on 8.12.2008, d) the company "MAGNETIC HYGEIA DIAGNOSTIC IMAGING S.A" consolidated for the first time with the purchase method due to its shareholding increase in March 2009 from 20% to 100% of its share capital and e) the company BIO-CHECK INTERNATIONAL Private Multi-Medical Facility Iatriki S.A., consolidated for the first time with the purchase method after acquiring control on 1.6.2009.</p> <p>The aforementioned companies are included in HYGEIA Group consolidated financial statements of the interim period 01.01-30.09.2009 and are not included in the respective comparable period of 2008.</p> <p>In June 2009, the terms of Genesis Group acquisition by the Diagnostic and Therapeutic Center of Athens-Hygeia S.A Group were finalized. Note that the goodwill resulting from this acquisition and exhibited on the Group's consolidated financial statements has been identified based on temporary values; its final assessment shall have been completed by the end of financial year 2009 (Note 9 of the Interim Financial Statements).</p> <p>In the current period, "MITERA S.A." has increased its shareholding in the subsidiary companies "LETO HOLDINGS S.A." and "LETO S.A." from 73.83% to 88.62% and from 32.90% to 43.99% respectively. Therefore, D.T.C.A. HYGEIA S.A indirect participation stake in these two companies increased from 72.76% to 87.34% and from 69.11% to 87.39%, respectively.</p> <p>2. During the 3Q2008, the fair value assessment of assets and recognized intangible assets and liabilities undertaken by MITERA S.A Group during the financial year 2007 was completed.</p> <p>Based on the values arising from the assessment, the Purchase Price Allocation (PPA) process in the respective accounts was performed along with a corresponding decrease of the initially recognized goodwill. As a result, the Income Statement for the period 30.09.2008 and the Group's Statement of Financial Position for the period ended on 30.09.2009 have been adjusted accordingly. Refer to Note 21 of the Interim Financial Statements Notes.</p> <p>3. D.T.C.A HYGEIA S.A BoD, at its meeting held on 02.12.2008, taking into consideration the circumstances prevailing in South-East European markets, unanimously resolved upon proceeding to early full redemption of the Convertible Bond Loan on the first annual issuing anniversary date (10.01.2009), in accordance with the terms of the relevant Information Bulletin. On 13.01.2009, the Company paid the full amount corresponding to the early full redemption standing at three hundred and six million fifteen thousand three hundred euro (€ 306,015,300), calculated according to its terms on 102% of each bond issuing price.</p> <p>4. On June 17, 2009 the Company's B' Reiterative Ordinary General Shareholders Meeting took place and decided to increase the Company's share capital in cash and with preemption right in favor of existing shareholders, by issuing 37,689,273 new common registered shares of €0.41 nominal value each, at share premium at the price of € 2.20 per share at a ratio of 3 new shares for every 10 existing Company shares; the Meeting also decided to amend article 5 of the Company's Articles of Association. Moreover, the above G.M proceeded to a revocation of the A' Reiterative Extraordinary General Shareholders Meeting decision held on January 22, 2009 on the share capital increase for regulatory reasons. The total coverage rate of the Share Capital Increase stood at 100% and the total amount of capital proceeds stood at € 82,916,400.6. The total amount of capital proceeds were used to cover part of the €306mn, paid to bondholders for the Convertible Bond Loan early full redemption. The Company's share capital now stands at €66,961,275.03, divided into 163,320,183 common registered shares of €0.41 nominal value each. The Company's 37,689,273 new common registered shares commenced trading on Athens Exchange on November 6, 2009.</p> <p>5. The most important legal disputes or disputes under arbitration, the judicial or arbitration bodies decisions having or likely to have a significant impact on the Company's or Group financial status or operation stand at approximately €58.2 mn and €118 mn respectively and pertain to claims by patients or the heirs thereof; such claims are covered by the insurance indemnity paid by insurance companies having concluded civil-professional liability (Mal Practice) contracts with physicians, and in addition, wherever required, the Mal Practice contract between the Company and the Greek subsidiaries (Clinics) may be evoked.</p> <p>The Company has formed a cumulative provision of about €2.6 mn for legal proceedings. The corresponding provision amount for the Group stands at €10.9 mn approximately. Beyond the already formed provision, no other substantial charges are anticipated from other Company and Group legal disputes or disputes under arbitration or from any court rulings.</p> <p>6. The Company has formed a cumulative provision of €1.2 mn for non tax audited financial years. The corresponding provision for the Group stands at approximately €1.9 mn. A relevant analysis for every company's non tax audited financial years is presented in note 17 of the Interim Financial Statements Notes.</p> <p>7. The Group and the Company have not formed other provisions, in the meaning of paragraphs 10, 11 and 14 of IAS 37 "Provisions, Contingent Liabilities and Contingent Assets".</p> <p>8. As of 30.09.2009 the Group headcount totaled 4,285 employees (30.09.2008: 2,673) and the Company's headcount totaled 1,167 employees (30.09.2008: 1,137), respectively.</p> <p>12. The other total revenues for the period 01.01-30.09.2009 amount to € (2,120,563) and concern Fx translation differences from converting subsidiaries financial statements into the parent company operation currency (euro). Respectively, total revenues amount to €11,321 for the period 01.01-30.09.2008.</p> <p>13. The Group and Company financial statements dated 30.09.2009 were approved by the Company's BoD on 18.11.2009.</p> <p>14. The annual financial statements basic accounting policies of financial year 2008 have been observed, except for the cases mentioned in note 3.2 of the Interim Financial Statements Notes.</p>									

9. The revenues/expenses amounts since the beginning of financial year 2009 resulting from transactions with related parties, according to IAS 24, are analyzed in the following table:

	Group	Company
Revenues	12,485	11,031,384
Expenses	0	15,915,124
Receivables	0	4,958,955
Liabilities	358,885	3,349,068
Transactions and senior executives and administration members' remuneration	4,543,677	1,849,665

10. There are liens &amp; encumbrances on the Group's fixed or real estate assets amounting to €20.7mn. There are no liens &amp; encumbrances on the Company's fixed or real estate assets.

11. In the direct changes of the Company's net worth, an amount of €1,161,539 concerns the convertible bond loan early repayment charge.

Marousi, November 18, 2009

BoD CHAIRMAN

GROUP CEO

GROUP CFO

DEPUTY CFO

HEAD ACCOUNTANT

KONSTANTINOS  
STAVROU  
ID card no A049114ARETI SOUVATZOGLOU  
ID card no N245069PANTELIS DIMOPOULOS  
ID card no AB606210ELEONORA KELEPOURI  
ID card no Σ028050IOANNIS ILIOPOULOS  
ID card no M059001